CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 11 enrolled
Drug / intervention
Placebo oral capsule +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03383887
NCT03383887Phase 2Completed
CompareCT.gov

Effect of DAW1033D on Obstructive Sleep Apnea and Its Phenotypic Traits

Brigham and Women's Hospital·interventional·Posted Dec 27, 2017·Updated Feb 25, 2020

In Brief

A Phase 2 clinical trial evaluating Placebo oral capsule and DAW1033D oral capsule for Obstructive Sleep Apnea (OSA). Completed, enrolled 11 participants across 1 site.

Detailed Summary

Obstructive sleep apnea (OSA) is common and has major health implications but treatment options are limited. OSA patients show a marked reduction in upper airway (UA) dilator muscle activity at sleep onset and this phenomenon leads to increased collapsibility of UA compared to normal subjects. In this protocol the investigators will test the effect of DAW1033D administered before sleep on OSA phenotype traits and OSA severity during sleep.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObstructive Sleep Apnea (OSA)
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedDec 27, 2017
Enrollment StartDec 13, 2017
Primary CompletionJan 20, 2020
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 8.5 years ago

Interventions

Placebo oral capsuledrug

Placebo before sleep

DAW1033D oral capsuledrug

DAW1033D before sleep